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ECONOMIC AND OUTCOMES ISSUES IN
CRITICAL CARE
CCI
SOCIOECONOMIC EFFICIENCY OF
PROPHYLAXIS OF EXACERBATIONS
WITH N-ACETYLCYSTEINE IN
PATIENTS WITH CHRONIC BRONCHITIS
Rappenhoner B, Bachinger A, Rychlik R
Institute of Empirical Health Economics. Odenthal. Genmany
The socioeconomic value of prophylaxis of acute exacer-
bations in patients with chronic recurrent bronchitis with
N-acetylcysteine (NAC) in comparison to no prophylaxis
is the subject of this analysis. In the case of an exacerba-
tion, therapy with the antibiotic amoxicillin was pre-
sumed.
METHODS: This decision tree analysis is based on a
meta-analysis, which described the probability and the
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frequency of an exacerbation either in the case of prophy-
laxis with NAC or no prophylaxis. Three sensitivity anal-
yses have been carried out. To check the stability of the
results of this cost-utility-analysis, therapy with arnoxicil-
lin was replaced by the antibiotic doxycycline. The daily
costs of NAC, which have a considerable influence on the
direct costs, were also varied. Finally, the influence of the
probability of inpatient therapy was analyzed.
RESULTS: Documented over a period of one year, pro-
phylaxis with NAC resulted in direct costs of 438.42
DM, whereas no prophylaxis caused direct costs of
266.82 DM. On the basis of indirect costs, prophylaxis
with NAC caused costs of 2,177.36 DM and no prophy-
laxis caused costs of 2,569.42 DM. The result of project-
ing these costs for the estimated 122,830 patients with
chronic recurrent bronchitis in the Federal Republic of
Germany reveals a potential of savings of total costs of
approximately 27.1 million DM in the case of a change
from no prophylaxis to prophylaxis with NAC.
CONCLUSION: This decision tree analysis reveals that
prophylaxis with NAC causes higher direct costs but in
long term it reduces the indirect costs by reducing the
time off work.
CC2
COST OF PREVENTABLE ADVERSE DRUG
EVENTS IN EMERGENCY DEPARTMENT
PATIENTS
Dominguez-Gil A, Bajo A, Otero MJ, Garcia-Gutierrez JF
Hospital Universitario de Salamanca. Salamanca. Spain
1-4% of all visits to emergency rooms are due to adverse
drug events (ADEs), but data about preventability and
cost due to preventable ADEs in this setting are limited.
OBJECTIVE: To determine the incidence of ADEs associ-
ated with emergency department (ED) visits and subse-
quent hospital admissions; to assess their preventability
and to estimate the costs of preventable ADEs to our in-
stitution, a 750-bed university tertiary care center.
METHODS: All patients who visited the ED from Octo-
ber 1995 to March 1996 were prospectively evaluated.
Recorded data included: medical and medication history,
laboratory data, serum drug concentrations, ED proce-
dures, intervention therapy, and characteristics and out-
come of ADEs. Patients admitted as a result of the ADE
were followed to collect information of invasive and non
invasive procedures, therapy, length of stay, and intensive
care. Preventable ADEs were analyzed to identify the as-
sociated factors. A cost analysis was performed.
RESULTS: From a total of 33,975 visits to the ED, 766
(2.25%) were due to ADEs. A total of 336 (43.9%) ADEs
were assessed as preventable; these resulted in 121 hospital
admissions, 1,575 stays, 121 ICU days, and 15 deaths. Inap-
propiate dose prescribed and inadequate monitoring of drug
therapy accounted for 46% and 31 % of preventable ADEs;
17% preventable ADEs were due to automedication. The
estimated hospital annual cost for all ADEs was $1.42 mil-
lion and for preventable ADEs was almost $1 million.
